It is also interesting that for patients with KRAS G12C-positive cancer, median OS for 1L CIT alone is numerically longer than 1L combination CIT and chemotherapy (30.2 months (14.5-NR) vs. 9.2 (5.9–14.0)), we postulate that one key difference in the tumor PD-L1 expression level might at least partially explain this observation. This evidence concerns the gene KRAS and neoplasm.